The content on this site is intended for healthcare professionals only
Maximizing survival in metastatic castration-resistant prostate cancer (mCRPC)
mCRPC: Challenges and opportunities in a booming area
Understanding the biology of the disease to guide treatment choices
Predictors of response to mCRPC therapy: where do we stand?
Managing mCRPC in daily practice: a pragmatic approach
Maximizing survival in metastatic Castration-Resistant Prostate Cancer: panel discussion
Immuno-Oncology: the next new paradigm in cancer treatment? Chairman's welcome and introduction
Cancer cells and the immune system: a natural story?
Why are Immuno-Oncology compounds different?
Immuno-Oncology: a concept or already a reality?
Chemosaturation therapy for cancers in the liver
Choosing the right treatment for each patient: The emergence of personalised healthcare in non-small cell lung cancer
The role of molecular pathways in therapeutic response and outcomes in breast cancer
Traditional and personalised models of therapy in gastrointestinal and endocrine tumours: the role of histological and clinical markers
Future perspectives: realising the potential of personalised healthcare in gynaecological cancer
The revolution in personalised healthcare: Towards improved outcomes in oncology: Conclusion and Summary
Radium-223: A breakthrough in treatment for advanced prostate cancer?
Genomic test to guide breast cancer treatment decisions approved in UK
What does NICE approval for Oncotype Dx in breast cancer mean?
Main final analysis from AZURE trial
Update on Anglo-Celtic Collaborative Oncology Group with overview of recent breast cancer trials
Brain mestastases from lung cancer ECC 2013
Where next in renal cell cancer with targeted therapies?
Real-world data with pazopanib confirm clinical trial findings in renal cell cancer
European Cancer Congress 2013 - News Roundup
Treating chest lymph nodes in early breast cancer improves survival without Increasing side effects
Evaluation of FIRE3 trial and ASPECT study in mCRC; implications in Japan
FIRE-3 trial: Analysis of KRAS/NRAS and BRAF mutations and the potential for biomarkers
Launch of the Institute of Cancer Policy
Stem cell therapy for prevention of radiation-induced salivary gland toxicity
Survival analysis of a follow-up phase III study of ipilimumab and dacarbazine in metastatic melanoma
Communicating with cancer patients
Development of bio-similar drugs
Molecular biology guiding treatment of gastrointestinal stromal tumours (GISTs)
Percutaneous Hepatic Perfusion: localised chemo for liver cancer
Overview of major cancer policy research at ECC 2013
Opportunity for mobile treatment setting for lymphoedema patients
Comparing the PLCO and ERSPC trials on efficacy of prostate cancer screening
The State of Oncology 2013
Lgr5 stem cells in self-renewal and cancer
Importance of the minimum data set in cancer nursing
The effects of communication technology on patients
Analysis of progression free survival versus overall survival in melanoma
New antibody drug, MPDL3280A, in non-small cell lung cancer
Prevention benefit from vitamin D
Meta-analysis of ipilimumab in metastatic or locally advanced, unresectable melanoma
Advances in patient management through web and mobile based applications
Standardised and centralised care of sarcomas
Biomarkers in the BOLERO3 trial
FLIMS workshop: Methods in clinical cancer research
Androgen blockade and ipilimumab against castration resistant prostate cancer
Observational RASTER study on the 70-gene-signature
Nursing highlights from ECC 2013
The 'Make Sense Campaign' for head and neck cancer awareness
TDM1 versus physicians choice in treatment in breast cancer
The State of Oncology 2013: a new report draws attention on disparities in cancer care
Aspirin may act on blood platelets to improve survival in colon cancer patients
Comment on prostate cancer screening from the ECC 2013 Scientific Co-Chair
Comment on primary site tumours from the ECC 2013 Scientific Co-Chair
Phase III trial, ICON6, shows cediranib improves survival in recurrent ovarian cancer
Research shows how aspirin may act on blood platelets to improve survival in colon cancer patients
ICON6 phase III trial shows cediranib improves survival in recurrent ovarian cancer
Comment on immunotherapy in lung cancer from the ECC 2013 Scientific Co-Chair
Identifying disease-causing mechanisms in cancers with unknown primary site improves treatment and survival
Prostate-specific antigen test 'does more harm than good'
Results for new antibody drug in non-small cell lung cancer
Prostate-specific antigen test 'does more harm than good'
Identifying disease-causing mechanisms in cancers with unknown primary site i
Impact of radiotherapy on loco-regional control
Fall in colorectal cancer death rates attributed to screening
Diabetes linked to increased risk and poorer outcomes in breast and colon cancer
Association between overall survival and government spending on cancer care
Cancer survival in Europe strongly associated with government spend on health care
Diabetes causes increased risk of developing and dying from breast and colon cancer
Evidence that fall in colorectal cancer death rates is attributable to screening programmes
ECC 2013 Preview: Oncopolicy, personalised medicine and nursing sessions at ECC 2013
ECC 2013 Preview: Importance of multidisciplinarity at ECC 2013
ECC 2013 Preview: Expectations for ECC 2013
ECC 2013 Preview: Scientific programme highlights
ECC 2013 Preview: Multidisciplinarity and the scientific programme
ECC 2013 Preview: Surgical oncology and the 'Patient Track'
